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Abstract 
Aims 
To investigate the association between day-to-day fasting self-monitored blood 
glucose (SMBG) variability and risk of hypoglycaemia in type 1 (T1D) and type 2 
diabetes (T2D), and compare day-to-day fasting SMBG variability between 
treatments with insulin degludec (degludec) and insulin glargine 100 units/mL 
(glargine U100). 
Materials and methods 
Data were retrieved from two double-blind, randomised, treat-to-target, two-period 
(32 weeks each) crossover trials of degludec versus glargine U100 in T1D 
(SWITCH 1, n=501) and T2D (SWITCH 2, n=720). Available fasting SMBGs were 
used to determine the standard deviation (SD) of day-to-day fasting SMBG variability 
for each patient and treatment combination. The association between day-to-day 
fasting SMBG variability and overall symptomatic, nocturnal symptomatic and severe 
hypoglycaemia was analysed for the pooled population using linear regression, and 
with fasting SMBG variability included as a three-level factor defined by population 
tertiles. Finally, day-to-day fasting SMBG variability was compared between 
treatments.  
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Results 
Linear regression showed that day-to-day fasting SMBG variability was significantly 
associated with overall symptomatic, nocturnal symptomatic, and severe 
hypoglycaemia risk in T1D and T2D (p<0.05). Day-to-day fasting SMBG variability  
was significantly associated (p<0.01) with all categories of hypoglycaemia risk, 
except for severe hypoglycaemia in T2D when analysed within tertiles. Degludec 
was associated with 4% lower day-to-day fasting SMBG variability than glargine 
U100 in T1D (p=0.0082) and 10% lower in T2D (p<0.0001).  
Conclusions 
Higher day-to-day fasting SMBG variability is associated with an increased risk of 
overall symptomatic, nocturnal symptomatic and severe hypoglycaemia. Degludec 
has significantly lower day-to-day fasting SMBG variability versus glargine U100. 
 
ClinicalTrials.gov numbers: NCT02034513 (SWITCH 1) and NCT02030600 
(SWITCH 2). 
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Introduction 
Diabetes, both type 1 (T1D) and type 2 (T2D), results in chronic hyperglycaemia 
placing patients at risk of diabetes-related complications,1-3 requiring treatment with 
glucose-lowering therapies. However, with tighter glycaemic control comes an 
elevated risk of hypoglycaemia and its associated problems.4 Hypoglycaemia is a 
major concern for patients and physicians,5 has significant negative effects on 
patients health and quality of life, and potentially increases risk of adverse 
cardiovascular (CV) events.5-7 The physical and psychological effects of 
hypoglycaemia make it a primary barrier to establishing glycaemic control.4 
Traditionally, management of diabetes has focused on HbA1c.8,9 As an average 
measure of glycaemia, HbA1c does not reflect the fluctuations in blood glucose 
(glycaemic variability) that more directly indicate a patients risk of hypoglycaemia or 
hyperglycaemia.9  
Glycaemic variability is determined by a multitude of interconnected factors, some 
inherent to the patient (physiology and behaviour) and their diabetes (remaining 
endogenous insulin secretion and insulin sensitivity), but also reflecting the 
pharmacodynamic glucose-lowering variability of treatment.9,10 Several studies have 
investigated the role of glycaemic variability on risk of complications; an association 
with microvascular complications has been demonstrated in patients with T2D, while 
conflicting results have been found in patients with T1D.11,12 Furthermore, in patients 
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with T2D, variability in fasting self-monitored blood glucose (SMBG) has been linked 
to an increased risk of mortality.13-15  
High day-to-day glycaemic variability exposes patients to risk of hypoglycaemia and 
is a frustrating issue for patients particularly in patients treated with  insulin.16 
Although  there may be debate about the most accurate metric of measuring 
glycaemic variability,9 one can expect that improved and simpler techniques will 
become more widely adopted when continuous glucose monitoring is more widely 
applied in research and clinical practice. Nonetheless, the consolidated evidence to-
date supports the importance of both the magnitude and duration of glucose 
variability,9 with respect to increased risk of hypoglycaemia, regardless of the 
method of variability measurement.15,18-22  
However, in many cases, studies of glucose variability have limitations in terms of 
the applicability of their findings to clinical practice. For example, many of these 
studies were limited by the relatively small numbers of patients studied.20-22 In 
addition, there is heterogeneity in the definition of hypoglycaemia used across 
studies, with some focused on symptomatic hypoglycaemia or episodes with blood 
glucose (BG) 70 mg/dL (3.9 mmol/L),18 and others investigating episodes of 
severe15,19and nocturnal hypoglycaemia.19,23  
A post hoc analysis of the two double-blind crossover trials of insulin degludec 
(degludec) versus insulin glargine 100 units/mL (glargine U100), in patients with T1D 
(SWITCH 1)24 and those with T2D (SWITCH 2)25 provided an opportunity to further 
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study the association between day-to-day fasting SMBG variability and the risk of 
hypoglycaemia  and to analyse the difference in day-to-day fasting SMBG variability 
between degludec and glargine U100. The SWITCH trials allowed the investigation 
of a broader range of definitions of hypoglycaemia, including previously studied 
severe15,19 and nocturnal hypoglycaemia,19,23 but also non-severe hypoglycaemia. 
Furthermore, the double-blind, crossover design adds to the validity of the data 
obtained in the SWITCH trials24,25 as it reduces the influence of inter-individual 
variability and investigator or patient bias on study outcomes. 
Materials and Methods 
SWITCH 1 and SWITCH 2 overviews 
Data were retrieved from two double-blind, randomised, two-period (32 weeks each) 
crossover, multicentre, treat-to-target clinical trials comparing degludec (100 
units/mL, Novo Nordisk, Denmark) once daily (OD) with glargine U100 (Sanofi, 
France) OD in patients with T1D (SWITCH 1, n=501),24 or in insulin-experienced 
patients with T2D (SWITCH 2, n=721),25 fulfilling at least one pre-specified risk 
criterion for hypoglycaemia. Detailed trial designs and methods were reported 
previously for SWITCH 124 and SWITCH 2.25 In SWITCH 1, mealtime insulin aspart 
(IAsp) was administered two- to four-times per day; in SWITCH 2, all pre-trial oral 
antidiabetic drugs (OADs, including any combination of metformin, dipeptidyl 
peptidase-4 inhibitor, alpha-glucosidase inhibitor, thiazolidinediones, and sodium 
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glucose cotransporter-2 inhibitor) were continued at the pre-trial dose throughout the 
trial. 
In both trials, the 64-week trial period consisted of treatment periods 1 and 2 
(32 weeks each, either with degludec or glargine U100). Each treatment period 
consisted of a 16-week titration period (Weeks 116 and Weeks 3248) and a 16-
week maintenance period (Weeks 1632 and Weeks 4864). Consistent with the 
pre-specified confirmatory analyses from the primary trial results,24,25 the fasting 
SMBG values and hypoglycaemic episodes in this post hoc analysis were retrieved 
from the two 16-week maintenance periods of both treatments (Weeks 1632 and 
Weeks 4864) in both trials (Supplemental Figure S1). During the maintenance 
periods, titration of basal insulin could be continued using the same glucose target 
(4.0ņ5.0 mmol/L [71ņ90 mg/dL]) and algorithm used in the titration periods.  
The trial protocols were approved according to local regulations by appropriate 
health authorities and by institutional review boards at all participating institutions, 
and conducted in accordance with the Declaration of Helsinki26 and Good Clinical 
Practice guidelines.27 Written informed consent from all patients was obtained before 
enrolment.  
Fasting SMBG 
In SWITCH 1, the lowest fasting SMBG values were used for weekly titration of basal 
insulin, whereas in SWITCH 2, the mean of the three fasting SMBG measurements 
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on three consecutive days before each contact were used for weekly titration of 
basal insulin. Therefore, up to seven fasting SMBG measurements per week were 
available for patients in SWITCH 1, and up to three fasting SMBG measurements 
per week were available for patients in SWITCH 2. Only patients with two or more 
fasting SMBG values within 1 week at least once during the maintenance periods 
contributed to the analyses. 
Statistical analyses of day-to-day fasting SMBG variability and hypoglycaemia 
To analyse the association between fasting SMBG variability and risk of 
hypoglycaemia, data were pooled regardless of the treatment allocation, but 
analysed separately for patients with T1D and those with T2D. For each patient and 
treatment combination, the standard deviation (SD) of the fasting SMBG was 
determined and used as the measure of day-to-day glycaemic variability. First, the 
weekly variances were calculated based on the log-transformed fasting SMBG 
values. The day-to-day fasting SMBG SD variability (for each patient and treatment 
combination) was defined as the square root of the mean value of the weekly 
variances of fasting SMBG values across the 16 weeks during the maintenance 
period, thereby obtaining an efficient estimate of the SD, which is not confounded by 
dose adjustments.  
A linear regression was initially performed to analyse the association between day-
to-day fasting SMBG variability and rate of hypoglycaemia using a Poisson model 
with logarithm of the exposure time (100 years) as offset. This model was an 
ǤǤ
 Page  of 34 
 
extension of the pre-specified confirmatory model used for the SWITCH trials24,25 
with the addition of adjusting for variability measure. This model included treatment, 
treatment period, sequence and dosing time as fixed effects, day-to-day fasting 
SMBG variability, as defined above, as a covariate, and patient as a random effect.  
Patients were also grouped into three tertiles, based on their day-to-day fasting 
SMBG variability values, as done in the previously published studies to allow 
comparison of these data.15,19 The rates of hypoglycaemia were analysed using the 
same model as that for the linear regression except that the day-to-day fasting 
SMBG SD variability was included as a fixed effect.  
A second measure of the day-to-day fasting SMBG variability was calculated as the 
geometric mean of the weekly coefficient of variation (CV%). Patients were then 
grouped into three equally sized tertiles, based on these values. The rates of 
hypoglycaemia were analysed using the same Poisson model as described above, 
except that the day-to-day fasting SMBG variability (CV%) was only evaluated as a 
fixed effect defined by tertiles.   
Hypoglycaemia episodes in the SWITCH trials were classified as follows: overall 
symptomatic, nocturnal symptomatic and severe hypoglycaemia. Overall 
symptomatic hypoglycaemia was defined as severe or BG-confirmed (<3.1 mmol/L 
[56 mg/dL]) symptomatic episodes; nocturnal symptomatic hypoglycaemia was 
defined as severe or BG-confirmed episodes in the time interval of 00:0105:59 am, 
both inclusive; severe hypoglycaemia was defined as events requiring third-party 
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assistance (based on the ADA definition).28 All severe episodes reported by 
investigators or identified via a predefined Medical Dictionary for Regulatory 
Activities version 18.1 search of safety data were adjudicated prospectively by an 
external Event Adjudication Committee; only those confirmed by adjudication were 
included in the analysis.  
Day-to-day fasting SMBG variability  and hypoglycaemia with degludec versus 
glargine U100 
The available fasting SMBG values during the maintenance period were also used to 
calculate the day-to-day fasting SMBG SD variability in the two treatment arms 
separately. The weekly day-to-day fasting SMBG variability estimates (SDs) were 
subsequently compared between degludec and glargine U100 using a linear mixed 
effect model with treatment, treatment period, sex, region (only in SWITCH 1), 
antidiabetic therapy at screening, visit and dosing time as fixed effects, age as a 
covariate, and patient as a random effect.  A similar treatment comparison was also 
conducted using the day-to-day fasting SMBG variability based on the CV% values. 
The rates of hypoglycaemia with degludec versus glargine U100 for each tertile were 
analysed using a Poison model with logarithm of the exposure time (100 years) as 
offset, with treatment, period, sequence, dosing time, fasting SMBG variability tertiles 
and its interaction with treatment as fixed effects and with patient as a random effect. 
In addition, the interaction between fasting SMBG variability and treatment was 
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investigated using a similar Poison model but with fasting SMBG variability on log 
scale as a linear regressor. 
Results 
In the SWITCH 1 and 2 trials, 16 and 6 patient and treatment combinations were 
excluded respectively from the statistical analysis due to too few reported SMBGs. 
Patients included in the analysis had sufficient data to calculate the SMBG SD 
values for at least 1 week for one period. Available SMBG variabilities were 
calculated on an average of 84 and 45 SMBG measurements per patient in SWITCH 
1 and 2, respectively. Baseline characteristics of the patients in each day-to-day 
fasting SMBG variability tertile are shown in Table 1. In patients with T1D, those in 
the higher day-to-day fasting SMBG variability tertile had longer durations of 
diabetes, were younger and had higher HbA1c values. In patients with T2D, a similar 
trend was observed for duration of diabetes and HbA1c values, but there was no link 
between day-to-day fasting SMBG variability and mean age or age groups. 
Day-to-day fasting SMBG variability and hypoglycaemia 
In patients with T1D, the rates of overall symptomatic, nocturnal symptomatic and 
severe hypoglycaemia all increased significantly with higher day-to-day fasting 
SMBG variability (SD values) in the linear regression analysis (Figure 1). In patients 
with T2D, the same significant association was seen across all hypoglycaemia 
categories (Figure 1). With a doubling of the day-to-day fasting SMBG variability (SD 
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values) , the risks of overall, nocturnal symptomatic and severe hypoglycaemia 
increased by 2.1-, 2.7-, and 2.0-fold for T1D, and 3.3-, 3.5-, and 1.9-fold for T2D, 
respectively (Supplemental Figure S2). 
In patients with T1D, the cumulative number of hypoglycaemic episodes per patient 
in the high tertile was higher than those for the patients in the low or medium tertiles 
during the maintenance period (Figure 2). Patients in the high day-to-day fasting 
SMBG variability tertile had a higher number of overall symptomatic, nocturnal 
symptomatic and severe hypoglycaemic episodes per 100 patient-years of exposure 
(PYE), compared with patients in the low or medium tertiles (Supplemental 
Figure S3). In patients with T1D, the day-to-day fasting SMBG variability was 
significantly associated with the rates of overall symptomatic (p<0.0001), nocturnal 
symptomatic (p<0.0001) and severe hypoglycaemia (p=0.0053, Table 2 and 
Supplemental Figure S3). 
In patients with T2D, similarly, patients in the high day-to-day fasting SMBG 
variability tertile had a higher cumulative number of hypoglycaemic episodes than 
those in the low or medium tertiles during the maintenance period (Figure 2). The 
lowest number of overall symptomatic, nocturnal symptomatic and severe 
hypoglycaemic episodes per 100 PYE were observed for the patients in the low day-
to-day fasting SMBG variability tertile (Supplemental Figure S3). Day-to-day fasting 
SMBG variability was significantly associated with overall and nocturnal symptomatic 
hypoglycaemia in patients with T2D (both p<0.0001, Table 2 and Supplemental 
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Figure S3). For severe hypoglycaemia, a similar pattern of an increased number of 
hypoglycaemic episodes per 100 PYE with higher day-to-day fasting SMBG 
variability was observed; however, it did not reach statistical significance in patients 
with T2D (p=0.1140, Table 2 and Supplemental Figure S3). 
In patients with T1D or T2D, a larger proportion in the high day-to-day fasting SMBG 
variability tertile had overall symptomatic, nocturnal symptomatic and severe 
hypoglycaemia than those in the low day-to-day fasting SMBG variability tertile 
(Supplemental Figure S3).  
The second measure of the day-to-day fasting SMBG variability using CV% values 
indicated the same effect on the risk of hypoglycaemia (Table 3). 
When adjusting for diabetes duration and eGFR at baseline, the significant 
association between fasting SMBG variability and overall and nocturnal symptomatic 
hypoglycaemia persisted.  
Day-to-day fasting SMBG variability and hypoglycaemia with degludec versus 
glargine U100 
In both trials, degludec was associated with significantly lower day-to-day fasting 
SMBG SD variability (T1D, variability ratio: 0.96 [0.93; 0.99]95% CI, p=0.0082; T2D, 
variability ratio: 0.90 [0.86; 0.93]95% CI, p<0.0001), compared with glargine U100. 
When using the CV% values as the measure of the day-to-day fasting SMBG 
variability, similar results were observed (T1D, variability ratio: 0.99 [0.97; 1.00]95% CI, 
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p=0.0783; T2D, variability ratio: 0.95 [0.93; 0.97]95% CI, p<0.0001) with degludec, 
compared with glargine U100. During the treatment with degludec, there were 31% 
patients with T1D and 30% patients with T2D in the high day-to-day fasting SMBG 
variability tertile; whereas during the treatment with glargine U100, there were 35% 
patients with T1D and 37% patients with T2D in the high day-to-day fasting SMBG 
variability tertile (Supplemental Figure S4). Day-to-day fasting SMBG variability was 
significantly associated with hypoglycaemia for all definitions, except for severe 
hypoglycaemia in T2D when analysed in variability tertiles. The non-significant 
interaction between fasting SMBG variability and treatment in most cases (Table S5) 
indicated that the fasting SMBG variability had the same effect for the two 
treatments, and its overall association with the risk of hypoglycaemia remained 
significant. There were comparable or lower rates of hypoglycaemia with degludec 
versus glargine U100 within all variability tertiles (Table S5).  
Discussion 
In these post hoc analyses, fasting SMBG values were used to quantify day-to-day 
fasting SMBG variability and evaluate its association with the risk of hypoglycaemia 
in patients with T1D and those with T2D. 
In the present analyses, day-to-day fasting SMBG variability was investigated as an 
indicator of basal insulin action, which is not influenced by food intake or 
medications, such as bolus insulins. The methods of statistical analyses used in this 
study were consistent with those used in the previous investigations of within-subject 
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day-to-day PK/PD variability of degludec and glargine U100 under clamp 
conditions.29 
A higher day-to-day fasting SMBG variability was significantly associated with an 
increased risk of overall symptomatic, nocturnal symptomatic and severe 
hypoglycaemia in patients with T1D and those with T2D. When day-to-day fasting 
SMBG variability tertiles were considered, similar results were seen, except for 
severe hypoglycaemia in patients with T2D where event rates were relatively low 
and this association was not significant, although a trend was observed. Findings in 
the current study are supported by a previous retrospective analysis of the Diabetes 
Control and Complications Trial (DCCT) data in patients in T1D,19 and a study 
assessing the association between glycaemic variability and risk of hypoglycaemia 
(glucose level <3.9 mmol/L [70 mg/dL]) using CGM data in patients with T1D or 
T2D,20 although these studies did not specifically investigate the variability of fasting 
glucose. While these other studies focused on mean glycaemic variability, in the 
present analysis fasting SMBG measurements were utilised as a measure of day-to-
day fasting glycaemic variability relating primarily to basal insulin effects. 
Prior to the publication of the results from the DEVOTE study,15 it was unknown 
whether fasting blood glucose variability confers additional risk for adverse events 
beyond those associated with chronic hyperglycaemia. Similar to the present study, 
DEVOTE demonstrated in patients with T2D at high CV risk, a significant association 
between risk of severe hypoglycaemia and the day-to-day glycaemic variability in 
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fasting SMBG.15 In this secondary analysis based on DEVOTE, it was also 
demonstrated that a higher day-to-day fasting glycaemic variability is associated with 
a higher risk of all-cause mortality.  
It is worth noting that the effect of fasting SMBG variability on the risk of 
hypoglycaemia appears to be the same for the two treatments, as indicated by the 
lack of interaction between treatment and fasting SMBG for most cases. The 
significantly lower day-to-day fasting SMBG variability of degludec compared with 
glargine U100 is consistent, both with the results from the PK/PD clamp trial in 
patients with T1D,29 and those from a previous prospective observational study in 
patients with T1D.30 In the clamp study, degludec had four-times lower day-to-day 
variability for the parameter of area under the glucose infusion rate curve during one 
dosing interval (AUCGIR0-24; CV 20%) than glargine U100 (CV 82%) under steady-
state conditions.29 The observation of lower fasting SMBG variability with degludec in 
the present analyses is probably explained by its lower day-to-day PD variability 
versus glargine U100.29,31 The lower rate of hypoglycaemia with degludec, reported 
in the original SWITCH (and other) trials,24,25,32,33 is also likely to be a consequence 
of its flatter and less variable action profile versus glargine U100.29 The reduced risk 
of hypoglycaemia due to the more stable PD of degludec may itself contribute to 
lower glycaemic variability by reducing the likelihood of patients over-treating 
hypoglycaemia and experiencing rebound post-hypoglycaemia hyperglycaemia. 
Thus, the PD profile of degludec may reduce both glycaemic variability and 
hypoglycaemia.  
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Strengths of these post hoc analyses based on the SWITCH trials include the 
crossover design of these trials, which reduces the influence of inter-individual 
variability on the obtained outcomes, and the double-blind design, which would 
reduce investigator and patient bias. Furthermore, the inclusion criteria of the 
SWITCH trials allowed for a broader patient population more closely resembling that 
encountered in clinical practice, than the cohorts typical of Phase 3 parallel-group 
trials. In addition, the number of patients included in these analyses were much 
larger than some of the previous studies in this area.20-22 In the SWITCH trials, the 
threshold for hypoglycaemic episodes was BG <3.1 mmol/L (56 mg/dL). This is 
consistent with the recent recommendations made by the International 
Hypoglycaemia Study Group whereby hypoglycaemic episodes with BG <3.0 mmol/L 
(54 mg/dL ) are considered clinically important.34 Furthermore, all severe 
hypoglycaemic episodes in these two trials were adjudicated by an external Event 
Adjudication Committee; only those confirmed by adjudication were included in these 
analyses. 
There are limitations to this study adding to the inherent limitation of a post hoc 
analysis, which is not pre-specified. Firstly, glycaemic variability was related solely to 
fasting SMBG, not allowing for analysis of the patients blood glucose levels 
throughout the day. Secondly, as mentioned in the Results, in the SWITCH 1 and 2 
trials, 16 and 6 patient and treatment combinations were excluded respectively due 
to too few reported SMBGs; however, given the large number of patients included 
and the number of SMBG measurements available per patient, it is believed that 
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sufficient data were used to calculate the SMBG SD values. Finally, other factors 
that may affect the fasting SMBG variability, such as exercise, food intake and 
stress, have not been investigated in the current study.  
In conclusion, these two post hoc analyses of SWITCH 1 and SWITCH 2 further 
establish the association between day-to-day fasting SMBG variability and risk of 
hypoglycaemia, showing that lower day-to-day fasting SMBG variability is 
significantly associated with lower risk of hypoglycaemia in patients with T1D or T2D. 
Clearly, treatment choices that reduce day-to-day fasting SMBG variability could 
contribute to a reduced risk of hypoglycaemia. For this reason, reducing glycaemic 
variability might be a useful additional clinical goal in the management of diabetes.  
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Figure legends 
Figure 1. Linear regression analysis on the effect of day-to-day fasting SMBG 
variability (SDs) on rate of hypoglycaemia 
Data were based on the full analysis set during the maintenance period.  
CI, confidence interval; RR, rate ratio; SMBG, self-monitored blood glucose; T1D, 
type 1 diabetes; T2D, type 2 diabetes. 
 
 
Figure 2. Cumulative number of hypoglycaemic episodes for patients in the 
low, medium or high day-to-day fasting SMBG variability tertile  
Based on the safety analysis set. The time-scale of Weeks 1632 is included in the 
x-axis, as only hypoglycaemic episodes during the maintenance periods were 
considered. All non-withdrawn patients had the same duration of exposure.  
SMBG, self-monitored blood glucose; T1D, type 1 diabetes; T2D, type 2 diabetes. 
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Table 1. Baseline characteristics of patients grouped by low, medium and high day-to-day fasting SMBG variability tertiles 
Characteristics 
Patients with T1D Patients with T2D 
Low day-to-day 
fasting SMBG 
variability 
tertile 
Medium day-to-
day fasting 
SMBG 
variability 
tertile 
High day-to-
day fasting 
SMBG 
variability 
tertile 
Low day-to-day 
fasting SMBG 
variability 
tertile 
Medium day-to-
day fasting 
SMBG 
variability 
tertile 
High day-to-
day fasting 
SMBG 
variability 
tertile 
Number of patients 189 217 199 288 325 292 
Number of combinations of 
patient and treatment, n (%) 
285 (100.0) 287 (100.0) 285 (100.0) 424 (100.0) 424 (100.0) 424 (100.0) 
Male, n (%) 169 (59.3) 156 (54.4) 139 (48.8) 241 (56.8) 213 (50.2) 219 (51.7) 
Race, n (%) 
White 
Black 
Asian 
Other 
 
270 (94.7) 
13 (4.6) 
2 (0.7) 
0 (0.0) 
 
258 (89.9) 
23 (8.0) 
1 (0.3) 
5 (1.7) 
 
266 (93.3) 
16 (5.6) 
1 (0.4) 
2 (0.7) 
 
344 (81.1) 
55 (13.0) 
19 (4.5) 
6 (1.3) 
 
340 (80.2) 
60 (14.2) 
16 (3.8) 
8 (1.8) 
 
342 (80.7) 
69 (16.3) 
3 (0.7) 
10 (2.4) 
Ethnicity: Hispanic or Latino, 
n (%) 
35 (12.3) 22 (7.7) 28 (9.8) 212 (50.0) 136 (32.1) 107 (25.2) 
Mean age, years 49.4 45.5 43.0 59.7 62.3 62.3 
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Age group  
1864 years, n (%)  
6584 years, n (%)  
>84 years, n (%) 
 
233 (81.8) 
52 (18.2) 
0 (0.0) 
 
265 (92.3) 
22 (7.7) 
0 (0.0) 
 
273 (95.8) 
12 (4.2) 
0 (0.0) 
 
294 (69.3) 
126 (29.7) 
4 (0.9) 
 
259 (61.1) 
163 (38.4) 
2 (0.5) 
 
247 (58.3) 
177 (41.7) 
0 (0.0) 
Body weight, kg 81.8 81.7 78.3 93.1 92.0 90.4 
BMI, kg/m2 27.8 27.8 26.7 32.5 32.3 31.9 
Duration of diabetes, years 21.0 22.9 25.3 12.7 13.8 15.6 
HbA1c, % 7.2 7.6 7.8 7.4 7.5 7.8 
HbA1c, mmol/mol 55.7 59.5 62.2 57.9 58.0 61.6 
FPG, mmol/L 9.3 9.5 9.5 7.9 7.4 7.4 
FPG, mg/dL 166.7 170.7 170.5 141.9 133.2 133.2 
eGFR, mL/min/1.73 m2 87.2 90.8 91.8 80.8 78.2 75.5 
Insulin treatment at 
screening 
CSII 
Basal 
IDet, n (%) 
NPH, n (%) 
Glargine U100, n (%) 
 
 
41 (14.4) 
244 (85.6) 
185 (64.9) 
58 (20.4) 
1 (0.4) 
 
 
59 (20.6) 
228 (79.4) 
172 (59.9) 
55 (19.2) 
1 (0.3) 
 
 
62 (21.8) 
223 (78.2) 
171 (60.0) 
52 (18.2) 
0 (0.0) 
 
 
 
424 (100.0) 
111 (26.2) 
47 (11.1) 
266 (62.7) 
 
 
 
424 (100.0) 
92 (21.7) 
31 (7.3) 
301 (71.0) 
 
 
 
424 (100.0) 
83 (19.6) 
26 (6.1) 
315 (74.3) 
Data were summarised for the full analysis set. The baseline characteristics data were pooled for two treatment arms and two 
maintenance periods, and only patient and treatment combinations with two or more fasting SMBG measurements available within 
1 week at least once during the maintenance periods contributed to the baseline data. C-peptide levels were not available to 
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determine baseline endogenous insulin production. Data are mean values.  
BMI, body mass index; CSII, continuous subcutaneous insulin infusion; eGFR, estimated glomerular filtration rate; FPG, fasting 
plasma glucose; IDet, insulin detemir; n, number of combinations of patient and treatment; NPH, neutral protamine Hagedorn; 
SMBG, self-monitored blood glucose; T1D, type 1 diabetes; T2D, type 2 diabetes. 
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Table 2. Effect of day-to-day fasting SMBG variability (SDs) on rate of hypoglycaemia by low, medium and high tertiles 
Hypoglycaemia 
Day-to-day fasting 
SMBG variability 
tertile  
Patients with T1D Patients with T2D 
Estimate 
[95% CI] 
p-value 
Estimate 
[95% CI] 
p-value 
Overall symptomatic 
Low 0.68 [0.58; 0.78] 
p<0.0001 
0.28 [0.20; 0.40] 
p<0.0001 Medium Reference Reference 
High 1.32 [1.19; 1.46] 2.23 [1.79; 2.78] 
Nocturnal 
symptomatic 
Low 0.45 [0.33; 0.62] 
p<0.0001 
0.18 [0.09; 0.36] 
p<0.0001 Medium Reference Reference 
High 1.59 [1.26; 2.01] 2.18 [1.56; 3.03] 
Severe 
Low 0.82 [0.49; 1.38] 
p=0.0053 
0.33 [0.09; 1.22] 
p=0.1140 Medium Reference Reference 
High 1.70 [1.11; 2.61] 1.31 [0.55; 3.09] 
Data were based on the full analysis set. The number of episodes was analysed using a Poisson Model with logarithm of the 
exposure time (100 years) as offset. The model included treatment, period, sequence, dosing time and SMBG as fixed effects, and 
participant as a random effect. SMBG was incorporated as a factor with three tertiles of the fasting SMBG variability, defined by the 
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tertiles the square root of the mean value of the weekly variances of fasting SMBG values across the 16 weeks during the 
maintenance period. 
CI, confidence interval; SMBG, self-monitored blood glucose; T1D, type 1 diabetes; T2D, type 2 diabetes. 
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Table 3. Effect of day-to-day fasting SMBG variability (CV%) on rate of hypoglycaemia by low, medium and high tertiles 
Hypoglycaemia 
Day-to-day fasting 
SMBG variability 
(CV%) tertile  
Patients with T1D Patients with T2D 
Estimate 
[95% CI] 
p-value 
Estimate 
[95% CI] 
p-value 
Overall symptomatic 
Low 0.69 [0.61; 0.78] 
p<0.0001 
0.31 [0.22; 0.44] 
p<0.0001 Medium Reference Reference 
High 1.18 [1.07; 1.30] 2.09 [1.67; 2.61] 
Nocturnal 
symptomatic 
Low 0.44 [0.33; 0.59] 
p<0.0001 
0.26 [0.14; 0.47] 
p<0.0001 Medium Reference Reference 
High 1.34 [1.08; 1.67] 2.05 [1.48; 2.84] 
Severe 
Low 0.59 [0.35; 0.98] 
p=0.0106 
0.68 [0.22; 2.11] 
p=0.2705 Medium Reference Reference 
High 1.28 [0.86; 1.90] 1.59 [0.65; 3.93] 
Data were based on the full analysis set. The number of episodes was analysed using a Poisson Model with logarithm of the 
exposure time (100 years) as offset. The model included treatment, period, sequence, dosing time and SMBG as fixed effects, and 
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participant as a random effect. SMBG was incorporated as a factor with three tertiles of the fasting SMBG variability, defined by the 
tertiles the geometric mean value of the weekly CV% of fasting SMBG values across the 16 weeks during the maintenance period. 
CI, confidence interval; CV, coefficient of variation; SMBG, self-monitored blood glucose; T1D, type 1 diabetes; T2D, type 2 
diabetes 
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